{"title":"下午讨论:剂量发现临床试验会议中的统计问题。","authors":"Anna Heath, Kelley M Kidwell","doi":"10.1177/17407745251350598","DOIUrl":null,"url":null,"abstract":"<p><p>The adoption of innovative, model-based, and computationally intensive clinical trial designs is challenged by barriers including clinician engagement, regulatory acceptance, dissemination beyond major research institutions, and patient accrual. This session explored strategies to overcome these barriers. Key approaches discussed included the development of user-friendly software and interactive platforms to enhance transparency, open sharing of algorithms, and recognition of software contributions in academic publishing. Building collaborations with stakeholders predisposed to innovation, fostering interdisciplinary communication, and producing complementary methodological and clinical publications were emphasized as essential steps. Practical considerations for trials with small sample sizes included the use of adaptive designs, individualized trials, and alternative optimization strategies when traditional theoretical assumptions are infeasible. A major theme of the discussion was the importance of model assumptions in innovative designs. Questions were raised about the sensitivity of results to these assumptions and the robustness of methods, particularly under limited sample sizes. Addressing this requires extensive simulation studies across varied scenarios to assess operating characteristics. The focus should be on achieving clinically meaningful goals-such as identifying effective dose regions-rather than perfect model specification. Speakers emphasized the need to acknowledge and, when feasible, test assumptions post hoc, integrating such verification as secondary objectives in trial design. An iterative scientific process was encouraged, recognizing that trials not only serve immediate clinical goals but also advance broader scientific understanding. Assumptions provide a principled foundation for methodology, but thoughtful scrutiny of their realism was urged, given the risk of relying on overly strong or untestable premises. The potential of metaheuristic algorithms was highlighted for efficiently identifying optimal designs across different model assumptions, supporting robustness evaluations. Practical implementation should adapt optimal designs to stakeholder needs while preserving acceptable statistical efficiency. In sum, advancing the adoption of innovative designs requires improved communication, infrastructure, and methodological transparency, alongside careful evaluation of model assumptions and robustness.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"17407745251350598"},"PeriodicalIF":2.2000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Afternoon discussion: Statistical issues in clinical trials conference on dose finding.\",\"authors\":\"Anna Heath, Kelley M Kidwell\",\"doi\":\"10.1177/17407745251350598\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The adoption of innovative, model-based, and computationally intensive clinical trial designs is challenged by barriers including clinician engagement, regulatory acceptance, dissemination beyond major research institutions, and patient accrual. This session explored strategies to overcome these barriers. Key approaches discussed included the development of user-friendly software and interactive platforms to enhance transparency, open sharing of algorithms, and recognition of software contributions in academic publishing. Building collaborations with stakeholders predisposed to innovation, fostering interdisciplinary communication, and producing complementary methodological and clinical publications were emphasized as essential steps. Practical considerations for trials with small sample sizes included the use of adaptive designs, individualized trials, and alternative optimization strategies when traditional theoretical assumptions are infeasible. A major theme of the discussion was the importance of model assumptions in innovative designs. Questions were raised about the sensitivity of results to these assumptions and the robustness of methods, particularly under limited sample sizes. Addressing this requires extensive simulation studies across varied scenarios to assess operating characteristics. The focus should be on achieving clinically meaningful goals-such as identifying effective dose regions-rather than perfect model specification. Speakers emphasized the need to acknowledge and, when feasible, test assumptions post hoc, integrating such verification as secondary objectives in trial design. An iterative scientific process was encouraged, recognizing that trials not only serve immediate clinical goals but also advance broader scientific understanding. Assumptions provide a principled foundation for methodology, but thoughtful scrutiny of their realism was urged, given the risk of relying on overly strong or untestable premises. The potential of metaheuristic algorithms was highlighted for efficiently identifying optimal designs across different model assumptions, supporting robustness evaluations. Practical implementation should adapt optimal designs to stakeholder needs while preserving acceptable statistical efficiency. In sum, advancing the adoption of innovative designs requires improved communication, infrastructure, and methodological transparency, alongside careful evaluation of model assumptions and robustness.</p>\",\"PeriodicalId\":10685,\"journal\":{\"name\":\"Clinical Trials\",\"volume\":\" \",\"pages\":\"17407745251350598\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Trials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17407745251350598\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17407745251350598","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Afternoon discussion: Statistical issues in clinical trials conference on dose finding.
The adoption of innovative, model-based, and computationally intensive clinical trial designs is challenged by barriers including clinician engagement, regulatory acceptance, dissemination beyond major research institutions, and patient accrual. This session explored strategies to overcome these barriers. Key approaches discussed included the development of user-friendly software and interactive platforms to enhance transparency, open sharing of algorithms, and recognition of software contributions in academic publishing. Building collaborations with stakeholders predisposed to innovation, fostering interdisciplinary communication, and producing complementary methodological and clinical publications were emphasized as essential steps. Practical considerations for trials with small sample sizes included the use of adaptive designs, individualized trials, and alternative optimization strategies when traditional theoretical assumptions are infeasible. A major theme of the discussion was the importance of model assumptions in innovative designs. Questions were raised about the sensitivity of results to these assumptions and the robustness of methods, particularly under limited sample sizes. Addressing this requires extensive simulation studies across varied scenarios to assess operating characteristics. The focus should be on achieving clinically meaningful goals-such as identifying effective dose regions-rather than perfect model specification. Speakers emphasized the need to acknowledge and, when feasible, test assumptions post hoc, integrating such verification as secondary objectives in trial design. An iterative scientific process was encouraged, recognizing that trials not only serve immediate clinical goals but also advance broader scientific understanding. Assumptions provide a principled foundation for methodology, but thoughtful scrutiny of their realism was urged, given the risk of relying on overly strong or untestable premises. The potential of metaheuristic algorithms was highlighted for efficiently identifying optimal designs across different model assumptions, supporting robustness evaluations. Practical implementation should adapt optimal designs to stakeholder needs while preserving acceptable statistical efficiency. In sum, advancing the adoption of innovative designs requires improved communication, infrastructure, and methodological transparency, alongside careful evaluation of model assumptions and robustness.
期刊介绍:
Clinical Trials is dedicated to advancing knowledge on the design and conduct of clinical trials related research methodologies. Covering the design, conduct, analysis, synthesis and evaluation of key methodologies, the journal remains on the cusp of the latest topics, including ethics, regulation and policy impact.